Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • TP53 multihit
TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms
Posted inHematology-Oncology news Pathology & Lab Medicine/Bệnh học

TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms

Posted by MedXY By MedXY 05/09/2026
A multicenter retrospective study suggests that MDS with isolated del(5q) and TP53 multihit alterations has substantially better survival than other low-blast TP53-multihit MDS, challenging how this subgroup should be classified.
Read More
  • TEE-Guided Chest Compression Targeting During ED Resuscitation Did Not Improve Clinical Outcomes in Out-of-Hospital Cardiac Arrest
  • 低剂量聚乙二醇用于住院患者肠道准备的有效性:一项多中心随机试验
  • Optimizing Busulfan Precision Dosing: A Synthesis of Real-World Pharmacokinetics, Obesity, and Drug Interactions
  • Ethnicity Influences Relapse-Free Survival in Immune-Mediated Thrombotic Thrombocytopenic Purpura
  • TP53 Multihit Does Not Fully Erase the Prognostic Advantage of Isolated del(5q) in Myelodysplastic Neoplasms
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in